№ lp_2_3_13096
File format: docx Character count: 22008 File size: 47 KB
The document provides supplementary materials and methods for a scientific study on tumor cell resistance mechanisms in response to trastuzumab-maytansinoid antibody-drug conjugates, detailing procedures and compound synthesis.
Note: Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Note: Year
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and Controlled Bystander Effect
Year: 2026
Field: Biotechnology / Pharmacology
Document type: Research article
Institution: Mersana Therapeutics
Authors: Aleksandr Yurkovetskiy, Natalya Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovaneysan, Charlie Bu, Alex Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Keywords: Antibody-drug conjugate, polymer, bystander effect, auristatin
Target organism: Human HER2-positive and low-HER2-expression tumors
Experimental models: Mice, rats, cynomolgus monkeys
Payload: Auristatin F-hydroxypropylamide
Drug-antibody ratio (DAR): 10–15
Comparative analysis: Trastuzumab-Dolaflexin vs ado-trastuzumab emtansine
Safety evaluation: Pharmacokinetics, tumor regressions, toxicity profile
Description: Original research article detailing the synthesis, characterization, and in vivo evaluation of Dolaflexin, an auristatin-based antibody-drug conjugate with a high drug-antibody ratio and controlled bystander effect, including comparative studies with existing ADC platforms.
Community Support Program for Chronically Homeless Individuals
Year: 2020
Region / City: Massachusetts
Topic: Healthcare, Homelessness Support
Document Type: Bulletin
Organization / Institution: Executive Office of Health and Human Services, MassHealth
Author: Daniel Tsai
Target Audience: Managed Care Entities, Behavioral Health Vendors, Healthcare Providers
Period of Validity: From January 1, 2021
Date of Approval: October 2020
Date of Changes: Not specified
Low Demand Housing Programs for Chronically Homeless Veterans
Year: 2026
Region: United States
Topic: Homelessness, Veteran Services, Supportive Housing
Document Type: FAQ / Guidance Document
Organization: U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans
Target Audience: Service providers, program staff, and policymakers
Program Model: Grant and Per Diem Low Demand (GPD-LD)
Focus: Housing retention, harm reduction, engagement of hard-to-reach veterans
Admission Criteria: No sobriety or treatment compliance required
Program Duration: Transitional, time-limited
Services Offered: Voluntary therapeutic services, housing support, peer mentoring, motivational engagement strategies
Safety Measures: Resident and staff safety policies, monitoring of contraband, non-punitive management of substance use
Guidance Availability: Online resources and technical assistance provided by VA
Memorandum on Exit Determination for Holyoke Public Schools from Chronically Underperforming Status, June 17, 2025
Year: 2025
Region / City: Holyoke, Massachusetts, United States
Document Type: Memorandum
Organization: Massachusetts Board of Elementary and Secondary Education
Author: Patrick Tutwiler, Interim Commissioner
Addressee: Members of the Board of Elementary and Secondary Education
Subject: Exit determination and transition of Holyoke Public Schools from chronically underperforming status and state receivership
Referenced Institution: Holyoke Public Schools
Related Governing Body: Holyoke School Committee
Prior Announcement Date: October 29, 2024
Board Meeting Date: June 24, 2025
Anticipated Exit Date: July 1, 2025
Key Participants Mentioned: Joshua A. Garcia; Dr. Yadilette Rivera Colón; Anthony Soto
Topics: trastuzumab-maytansinoid antibody-drug Chronically